Piper Sandler analyst Yasmeen Rahimi raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $400 from $336 and keeps an Overweight rating on the shares. On the heels of Madrigal reporting preliminary net REZDIFFRA sales of about $100M-$103M and $177M-$180M, the firm believes 2025 should be a key year of growth for the stock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Akero cirrhosis data positive for Madrigal, says Piper Sandler
- Madrigal dip on Akero data a buying opportunity, says Evercore ISI
- Madrigal Pharmaceuticals’ Treatment Could Be a Blockbuster in the Making
- Madrigal Pharmaceuticals price target raised to $392 from $360 at Evercore ISI
- Madrigal price target raised to $400 from $390 at H.C. Wainwright